Where the power of nature meets the logic of science for the betterment of health.
ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to our ingredient technologies unit, we also have business units focused on natural product fine chemicals, chemistry and analytical testing services, and product regulatory and safety consulting. As a result of our relationships with leading universities and research institutions, we are able to discover and acquire early stage, ingredient technologies that are protected by intellectual property.... More »

Stock Quote
Change (%) Stock is Down 0.24 (4.23%)
Refresh quote
Real-Time Level 2 Quote
Recent NewsMore »
01/08/18ChromaDex and Watsons Expand Partnership with TRU NIAGEN™ Retail Launch in Singapore
After launching in Hong Kong in September, Watsons expands TRU NIAGEN™ retail distribution to Singapore IRVINE, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), a fully integrated, science-based, nutraceutical company devoted to improving the way people age, announced the launch of TRU NIAGEN™ in Singapore with its retail partner, Watsons. Singapore is the second Asian market for the U.S. made dietary supplement, after Hong Kong. With over 6,000 stores in 11 Asian a... 
Printer Friendly Version
12/14/17Published Study Reveals NIAGEN® Nicotinamide Riboside is an Effective NAD Precursor to Protect Cardiac Function in an Animal Model of Heart Failure
New Research Suggests the Protective Benefits of NR May Lead to a New Therapeutic Option in Human Heart Failure IRVINE, Calif., Dec. 14, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), a fully integrated, science-based, nutraceutical company devoted to improving the way people age, announced important cardiac research by Dr. Mathias Mericksay and colleagues at the l’Université Paris-Sud, and Dr. Charles Brenner and colleagues at the University of Iowa, published in the journal Circula... 
Printer Friendly Version
12/08/17Nicotinamide Riboside Shown to Improve Mitochondrial Energy Production and Memory in Alzheimer’s Disease Research
IRVINE, Calif., Dec. 08, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), a science-based, fully integrated nutraceutical company devoted to extending human healthspan, announced today that in research published in the journal Nature, Dr. Johan Auwerx showed that Alzheimer’s disease (AD) mice treated with nicotinamide riboside (NR) had lower levels of amyloid deposits, improved mitochondrial energy production and improved memory. Alzheimer’s disease is a devastating age-related neurode... 
Printer Friendly Version
Upcoming EventsMore »

There are currently no events scheduled.

What's New
Download Documentation2017 Q3 Quarterly Report on Form 10Q
Download DocumentationSpecial Meeting – Proxy Statement
Download Documentation2017 Proxy Statement
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Chromadex Corp posts new information to the site. Just enter your e-mail address and click Submit.
Data provided by Nasdaq. Minimum 15 minutes delayed.